The Role of Milk Derived Peptides on Glycaemic Control

NCT ID: NCT03102463

Last Updated: 2017-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to ascertain the potential of novel milk derived hydrolysates to improve glycaemic control to promote metabolic health. A comprehensive characterisation of the metabolic response to these milk derived hydrolysates will ascertain the effect of the hydrolysates in terms of insulin sensitivity. These hydrolysates have been shown to improve insulin resistance in cell and animal models. Therefore the investigators aim is to test their efficacy in overweight, insulin resistant individuals at risk of developing type 2 diabetes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recent figures estimate 60% of Irish adults are overweight or obese. As obesity is associated with the development of insulin resistance, which precedes type 2 diabetes development by decades, novel food based solutions are required to improve glycaemic control and attenuate insulin resistance.

In the current study insulin resistant individuals will undergo 4 study visits, 1 screening visit and 3 subsequent visits. At each of the 3 visits they will receive an oral lipid load consisting of 100mL soya bean oil, followed by either a water control; the hydrolysate being tested or the parent protein from which the hydrolysate was derived. After which they will undergo a 4 hour hyperinsulinemic-euglycaemic clamp at each visit to assess their insulin sensitivity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Water Control

Group Type SHAM_COMPARATOR

Water Control

Intervention Type DIETARY_SUPPLEMENT

120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp

Lipid Load

Intervention Type OTHER

100mL oral lipid load

Milk derived hydrolysate

Group Type ACTIVE_COMPARATOR

Milk derived hydrolysate

Intervention Type DIETARY_SUPPLEMENT

Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp

Lipid Load

Intervention Type OTHER

100mL oral lipid load

Parent Protein

Group Type ACTIVE_COMPARATOR

Parent Protein

Intervention Type DIETARY_SUPPLEMENT

Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp

Lipid Load

Intervention Type OTHER

100mL oral lipid load

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Water Control

120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp

Intervention Type DIETARY_SUPPLEMENT

Milk derived hydrolysate

Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp

Intervention Type DIETARY_SUPPLEMENT

Parent Protein

Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp

Intervention Type DIETARY_SUPPLEMENT

Lipid Load

100mL oral lipid load

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 - 65 years
* BMI \> 26 kg/m2
* Prepared to maintain a constant body weight for the duration of the study
* Free of any chronic or infectious disease
* Not taking any medication for the regulation of blood sugars
* Diet controlled type 2 diabetes
* Free of any milk allergies or lactose intolerance
* Without anaemia

Exclusion Criteria

* \<18 or \>65 years
* Diabetes (pharmacologically treated) or other endocrine disorders.
* Chronic inflammatory conditions.
* Kidney or liver dysfunction.
* Anaemia (Haemoglobin \<12g/dl men, \< 11g/dl women).
* Taking any medication for the regulation of blood sugars.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Enterprise Ireland

OTHER_GOV

Sponsor Role collaborator

University College Dublin

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof Helen M Roche

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Helen M Roche, PhD

Role: PRINCIPAL_INVESTIGATOR

University College Dublin

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St Vincent's University Hospital

Dublin, , Ireland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Ireland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FHI-3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Lactose on Blood Lipids
NCT04924530 COMPLETED NA